Presentation to Merrion Pharma 5 Jan 2008 v1[1]

8/17/2019 Presentation to Merrion Pharma 5 Jan 2008 v1[1]

1/25

Proposal

to

Merrion Pharmaceuticals plcby

Bloxham


2/25

2

Overview Part I - Profle o Bloxham

Part II - Overview o Merrion Pharmceuticals plc

Market Perception

The Key Issues acing the ompany

Part III - Proposal to Merrion!hat Bloxham will "ring to Merrion

Marketing an# $eman# %eneration or the %roup&s 'hares

Our role in long term #evelopment ( support o the %roup

Part I) - The Bloxham Team

onclusion


3/25

3

Part I - Introducing Bloxham


4/25

4

Bloxham Overview & Key Businesses

In#epen#ent Irish stock"roker with origins #ating "ack over*++ years

Bloxham is a partnership an# we are in#epen#ent o any"anking group

Institutional ,uities . *+/ market share in Irish euity market

0o1 * in Institutional Bon#s in $u"lin

'u"stantial !ealth Management ( Private lient "usinesses

2ocal 'ponsor Broker an# orporate 3inance 4#viser

Over 56"n un#er management in !ealth management (Private clients


5/25

5

Corporate Finance ActivitiesAdvisory & Transaction Management

Our corporate a#visory work with "oth uote# an# private plcsinclu#es a#vising companies on7

Fundraisings & placements

IOs and !econdary "istings

Buyouts

Ac#uisitions & $isposals

Corporate %overnance & !trategic and Financial

Advice

,xperience# in structuring an# executing transactions with

particular expertise working with growth oriente# "usinesses


6/25

6

Corporate Finance Credentials#uity Capital 'aisings

!e have access to all capital markets segments with aull range o euity8 euity relate# an# fxe# income

securities a#vising companies on7

rimary and !econdary Fundraisings

rivate lacements Institutional and rivate Client $eal

structures

Buyouts (nance

Tax )ased *undraisings !e have arrange# innovative an# complex solution

where appropriate an# tailore# to the specifc situation


7/25

7

Institutional #uities+Corporate Bro,ing

!e act as 'ponsor Broker on the Irish 'tock ,xchangeto ully liste# an# I,9 tra#e# companies1 #uity lacings & IO Fundraisings Investors 'elations rogrammes Mar,et related advice

!e are "roker to 7- FB$ -oldings plc .orld!preads %roup plc

Ogles)y & Butler %roup plc :ecent 4##itions o !orl#'prea#s %roup to I,9

'ecure# I,9 4#visor 'tatus earlier this year


8/25

8

Institutional #uities

3astest growing "roker in the institutional market with

highly regar#e#8 un"iase#8 an# in#epen#ent a#vise

*+/ share o Irish ,uity Market

,xtensive lient "ase covering all ma;or local an#International institutions


9/25


10/25

&%

Institutional Bonds 0um"er * Institutional Bon#


11/25

&&

.ealth Management & rivate Client)usinesses Bloxham has a long track recor# in un# ( portolio

management acting on #iscretionary or execution "asis

!ealth Management #ivision ocuses on Bloxham ownmanage# Investment 3un# pro#ucts

Private lients manages all aspects


12/25

12

Part II - Merrion Pharmaceuticals plc


13/25

13

Profile of the Company


14/25

14

Market Perception 3ollowing initial post IPO enthusiam ompany has experience

all oC in interest in its shares an# it has un#erperorme#

'hares a#versely aCecte# "y the all out o smaller capstocks an# also the current poor market con#itions

Market has overlooke# the ompany "ecause o these pointsan# also pro"a"ly its sector

The Market has not properly rewar#e# the ompany or itsachievements

0or has it recognise# the signifcant value potential ompanyhas1


15/25


16/25

1#

Part III - Proposal to MerrionPharmaceuticals


17/25

17

$ur %pproach to &ole of Broker an' !() %'*iser !e will act as a#viser to the ompany on I,9 market rules8 share tra#ing

matters an# on corporate transactions

!e liase with the Irish 'tock ,xchange on "ehal o the ompany on all

transactions8 market compliance an# regulators matters

!e will review all the ompany&s announcements an# a#vise on

presentation o matters to investors

!e will en#eavour to work with our 4IM noma#?"roker counterpart an#coor#inate #ealings on market matters or the maximum transactions"eneft o the ompany

!e will provi#e a share #ealing service an# en#eavour to make a marketin the shares an# arrange or "uyer?sellers to support market in theompany shares1


18/25


19/25

19

ey Messa"es must tell the Market Merrion is an Irish success story - uniue in #eveloping

me#ical #evice pro#ucts with state o the art technology an# IP

ompany is now poise# or a very signifcant positive up lit insales an# profta"ility over the next *= to *A months

ompany is not as expose# to market #ownturn as tra#itionalsectors stock is on the cusp o a ma;or perormance lit oC1

4n a##itional listing will sen# a positive signal to the Market

an# reinorce the key un#amental investment story an#

It will potentially expan# its sharehol#er "ase siHa"ly resultingin a avoura"le increase in market liui#ity an# share tra#ing#eman# or Merrion&s shares


20/25

2.

&atin"/0aluation ey ri*ers

'i(uidit Market !entiment generall Peer grou) rating Small ca) Stock "(uit rai!ed *uture )ro!)ect! +i!toric )er#ormance

Perce)tion o# management Minorit intere!t! ,a)ital rowth. ,a!h /ividend PO. 0e value driver!


21/25

21

Bloxham &ole

1dvi!or 2 Inve!tor elation!

orporate Broking :esults an#'trategy ommunication Investorrelationships

'ta"le highuality investor"ase

4#vocate role?con#uit o

inormation


22/25

22

Bloxham $*er*ie- ey business

Part I) - The Bloxham Team


23/25

$3

The Bloxham Team

Patrick Dempsey, Partner, Institutional Equities

Pa##y ;oine# Bloxham in 'eptem"er =++> as a partner o the frm an#

hea# o Institutional ,uities1 Pa##y is responsi"le or the management othe ,uity 'ales8 ,uity Tra#ing an# :esearch groups within Bloxham1Pa##y ;oine# Bloxham rom $avy8 were he hea#e# up ,uropeanInstitutional ,uity 'ales an# was also a sharehol#er o the %roup1


24/25

$4

The Bloxham TeamKevin cConnell, Head of !esearc"

Kevin8 a hartere# 3inancial 4nalyst8 is hea# o ,uity :esearch at

Bloxham 'tock"rokers since =++*1


25/25

25

Warning: Bloxham does not make any representation or warranty, express or implied, as to,

or assume any responsibility for, the accuracy, reliability or completeness of any of the aboveinformation or any other information contained in this document and will be under no

obligation to update or correct any inaccuracy in the information or be otherwise liable toyou or any other person in respect of the contents of this document. No statements orrepresentations made in this document are legally binding between Bloxham and the

recipient. Any proposal is subect to contract terms being agreed.

/i!claimer

Warning: !ast performance is not a reliable indicator of future performance. "he value of

investments and the level of income from them may go down as well as up and an investormay not get back the amount originally invested. #eturns may increase or decrease as aresult of currency fluctuations and general market trends.

Documents

Presentation to Merrion Pharma 5 Jan 2008 v1[1]